One of the US’s leading vaccine candidates AstraZeneca has moved on to stage III or final-stage clinical trial of its COVID-19 vaccine in the US.
AstraZeneca’s novel coronavirus jab – based on an adenovirus – will now be tried on up to 30,000 adults, aged 18 and over, to check the efficacy, safety, and immunogenicity of the vaccine against COVID-19, the company says in a statement.
The AZD1222 vaccine, co-developed by the Oxford University and AstraZeneca is one of the numerous candidates at their advanced stages of a clinical trial.
The UK-counterpart of the same vaccine is also underway and could yield results as early as next month, Bloomberg reported, along with trials beginning in Brazil, and South Africa.
Together with the US phase III trials, the AZD1222 vaccine will be inoculated on over 50,000 candidates across the world. People enrolled in the trial will either get the vaccine or saline for a placebo.
“Should clinical trials demonstrate the vaccine protects against COVID-19 disease and is approved for use, we will work hard to make it globally available in a fair and equitable manner as rapidly as possible,” Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said.
Participating centers of the vaccine will recruit at most 30k candidates from across the US to sample a population with diverse ethnic, geographic, and racial backgrounds.
Candidates will be a medley of health, as well as people with underlying ailments like HIV and diseases that increase the risk of COVID-19.
President Trump took the credit of fastraking the vaccine development which usually takes years to come at this present stage of development.
“In the United States we are doing things that people thought were not possible,” President Trump said at a White House press briefing.
All the advanced vaccine for the novel coronavirus in the US is being implemented under the Trump administration’s Operation Wrap speed which aims to fast forward the usually tedious process to make an effective vaccine.
AstraZeneca’s phase III trials have been delayed owing to some political hindrances in the past weeks, which Bloomberg noted was because the US administrations planned to grant emergency use authorization of the vaccine on the results of the UK trial.
AstraZeneca and Oxford University vaccine for the Indian market was also put to test later last month where two men were inoculated with the vaccine at India’s Bharati Vidyapeeth Medical College and Hospital.
“Since yesterday our medical team is in touch with two volunteers and both are fine. They do not have any pain fever injection side reaction or systemic illness post-vaccination,” Dr. Jitendra Oswal, deputy medical director of Bharati Vidyapeeth Medical College told PTI.